Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Skin Neoplasms × bempegaldesleukin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 5 Squamous Cell Carcinoma of Head and Neck 3 Neoplasm Metastasis 3 Carcinoma, Renal Cell 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Skin Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Neuroblastoma 1 Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, B-Cell 1 Leukemia 1 Kidney Neoplasms 1 Glioma 1 Ependymoma 1 Carcinoma, Merkel Cell 1

Interventions

aldesleukin 14 Cyclophosphamide 14 fludarabine phosphate 11 fludarabine 11 Interleukin-2 9 Ipilimumab 6 Temozolomide 4 Nivolumab 4 trametinib 2 sonidegib 2 pembrolizumab 2 dabrafenib 2 binimetinib 2 Whole-Body Irradiation 2 Vemurafenib 2 Tacrolimus 2 Sodium Chloride 2 Sirolimus 2 Radiotherapy 2 Radiation 2 Peptides 2 Gefitinib 2 Fluorouracil 2 Dacarbazine 2 Cyclosporine 2 Capecitabine 2 veliparib 1 varlilumab 1 tilsotolimod 1 spartalizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04410445 2023-04-21

PIVOT-12

Nektar Therapeutics

Phase 3 Terminated

765 enrolled 13 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡